Search Results for: APP

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
PLK1 polo like kinase 1
  • Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal
  • Polo-like kinase mediated events
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Phosphorylation of the APC/C
  • Phosphorylation of Emi1
  • Condensation of Prophase Chromosomes
  • Separation of Sister Chromatids
  • Resolution of Sister Chromatid Cohesion
  • Regulation of PLK1 Activity at G2/M Transition
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • RHO GTPases Activate Formins
  • Mitotic Prometaphase
  • Mitotic Metaphase/Anaphase Transition
  • Mitotic Telophase/Cytokinesis
  • Cyclin A/B1/B2 associated events during G2/M transition
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • EML4 and NUDC in mitotic spindle formation
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • 3-[3-chloro-5-(5-{[(1S)-1-phenylethyl]amino}isoxazolo[5,4-c]pyridin-3-yl)phenyl]propan-1-ol
  • 3-[3-(3-methyl-6-{[(1S)-1-phenylethyl]amino}-1H-pyrazolo[4,3-c]pyridin-1-yl)phenyl]propanamide
  • 4-(4-METHYLPIPERAZIN-1-YL)-N-[5-(2-THIENYLACETYL)-1,5-DIHYDROPYRROLO[3,4-C]PYRAZOL-3-YL]BENZAMIDE
  • 1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea
  • Wortmannin
  • Fostamatinib
  • Volasertib
PLK2 polo like kinase 2
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • CD163 mediating an anti-inflammatory response
  • NPAS4 regulates expression of target genes
  • Fostamatinib
PLPP3 phospholipid phosphatase 3
  • Sphingolipid catabolism
PLRG1 pleiotropic regulator 1
  • mRNA Splicing - Major Pathway
PLS3 plastin 3
PLSCR1 phospholipid scramblase 1
PNKD PNKD metallo-beta-lactamase domain containing
  • Primary torsion dystonia (PTD)
PNKP polynucleotide kinase 3'-phosphatase
  • APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway
  • Early infantile epileptic encephalopathy; Ohtahara syndrome
PNMA8A PNMA family member 8A
PNPO pyridoxamine 5'-phosphate oxidase
  • Vitamin B6 activation to pyridoxal phosphate
  • Pyridoxal phosphate
  • Flavin mononucleotide
  • Mercaptoethanol
PNRC2 proline rich nuclear receptor coactivator 2
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
POGK pogo transposable element derived with KRAB domain
POGZ pogo transposable element derived with ZNF domain
POLA2 DNA polymerase alpha 2, accessory subunit
  • Inhibition of replication initiation of damaged DNA by RB1/E2F1
  • Polymerase switching on the C-strand of the telomere
  • Telomere C-strand synthesis initiation
  • DNA replication initiation
  • Activation of the pre-replicative complex
  • Polymerase switching
  • Removal of the Flap Intermediate
  • Processive synthesis on the lagging strand
  • Defective pyroptosis
  • Dacarbazine
POLD3 DNA polymerase delta 3, accessory subunit
  • Recognition of DNA damage by PCNA-containing replication complex
  • Polymerase switching on the C-strand of the telomere
  • Processive synthesis on the C-strand of the telomere
  • Telomere C-strand (Lagging Strand) Synthesis
  • Removal of the Flap Intermediate from the C-strand
  • Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)
  • Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)
  • PCNA-Dependent Long Patch Base Excision Repair
  • Termination of translesion DNA synthesis
  • HDR through Homologous Recombination (HRR)
  • Gap-filling DNA repair synthesis and ligation in GG-NER
  • Dual Incision in GG-NER
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • Polymerase switching
  • Removal of the Flap Intermediate
  • Processive synthesis on the lagging strand
POLDIP2 DNA polymerase delta interacting protein 2
POLE3 DNA polymerase epsilon 3, accessory subunit
  • Recognition of DNA damage by PCNA-containing replication complex
  • PCNA-Dependent Long Patch Base Excision Repair
  • Termination of translesion DNA synthesis
  • HDR through Homologous Recombination (HRR)
  • Gap-filling DNA repair synthesis and ligation in GG-NER
  • Dual Incision in GG-NER
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • DNA replication initiation
  • Activation of the pre-replicative complex
  • Cladribine
POLH DNA polymerase eta
  • Translesion Synthesis by POLH
  • Termination of translesion DNA synthesis
  • HDR through Homologous Recombination (HRR)
  • Disorders of nucleotide excision repair, including: Xeroderma pigmentosum (XP); Cockayne syndrome (CS); UV-sensitive syndrome (UVS); Trichothiodystrophy (TTD); Cerebro-oculo-facio-skeletal syndrome (COFS); XFE progeroid syndrome
POLI DNA polymerase iota
  • Translesion synthesis by POLI
  • Termination of translesion DNA synthesis
POLL DNA polymerase lambda
  • Nonhomologous End-Joining (NHEJ)

Page 69 out of 106 pages